Pharma-Bio Serv (PBSV) Equity Average (2016 - 2026)
Pharma-Bio Serv (PBSV) has disclosed Equity Average for 12 consecutive years, with $11.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 13.0% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Oct 2025, down 13.0%, and an annual FY2025 reading of $12.8 million, down 14.12% over the prior year.
- Equity Average was $11.9 million for Q4 2025 at Pharma-Bio Serv, down from $12.0 million in the prior quarter.
- Across five years, Equity Average topped out at $22.7 million in Q3 2021 and bottomed at $11.9 million in Q4 2025.
- Average Equity Average over 5 years is $16.3 million, with a median of $16.1 million recorded in 2022.
- The sharpest move saw Equity Average grew 5.44% in 2021, then fell 29.4% in 2022.
- Year by year, Equity Average stood at $21.4 million in 2021, then decreased by 23.5% to $16.4 million in 2022, then dropped by 1.2% to $16.2 million in 2023, then fell by 15.2% to $13.7 million in 2024, then decreased by 13.0% to $11.9 million in 2025.
- Business Quant data shows Equity Average for PBSV at $11.9 million in Q4 2025, $12.0 million in Q3 2025, and $12.1 million in Q2 2025.